Empfehlung und Kommentare


Kursrakete Advanced Viral Research Corp. vor dem Start?

Advanced Viral Res Corp. (advr)

Verfasst am: 04.10.2007 - 11:59 Uhr von Chefkoch | Gelesen: 141376 | Gelesen heute: 1142 | Beiträge: 5
Letzter Kommentar von: Chefkoch am um 11:02 Uhr
Rating: KAUFEN
Kursziel: 0.05 €
Risiko: Hoch
Horizont: mittelfristig
Advanced Viral Research Corp. ein Biotechnologie Unternehmen mit einem interessanten Patent im Portfolio. Das Unternehmen mit Sitz in New York forscht an einem Produkt mit dem Namen AVR118. VR118 repräsentiert eine neue Art der Biopolymeren Chemie.

Das Produkt AVR118 soll beim Aufbau des Gewichtes, welches bei Krankheiten wie z. B. HIV oder Krebs schwindet, helfen. Weiter soll das Immunsystem damit stimuliert werden um Krebszellen, inbesondere Krebszellen die nach einer Chemotherapie beschädigt worden sind, abzutöten.

Daneben kann das Produkt gegen Genitalwarzen, Leukämie Erkrankungen eingesetzt werden.

Das Unternehmen ist an der OTCBB mit ca. 700 Mio. Shares gelistet. Mehr Infos zum Unternehmen gibt unter:

Laut Yahoo halten Insider ca. 18 % der Shares.

Top Institutionellen:
Holder Shares % Out Value* Reported
BAHL & GAYNOR, INC. 950,000 .13 $38,000 30-Jun-07
Geduld, Emanuel, E. 250,000 .03 $10,000 30-Jun-07
FIRST MANHATTAN COMPANY 36,000 .00 $1,440 30-Jun-07
Ameriprise Financial, Inc. 5,000 .00 $200 30-Jun-07

Momentan hat ADVR eine Marktkapitalisierung von 17 Mio. US Dollar, eigentlich recht gering für einen Biotech-Wert mit einem Produkt mit Blockbuster Qualität.

Ich gehe davon aus das in den nächsten Wochen Schub in den Kurs kommt.
Eine MK von 40 - 50 Mio. US Dollar wären meiner Meinung nach jetzt fair bewertet.

Spekulative Anleger gönnen sich eine erste Position. Stoppkurs bei  0.018 US Dollar.
Nach dem Chartbild hat sich ein doppelter Boden gebildet. 


Viel Glück!

Kommentare & Diskussion

Chefkoch am 04.10.2007 - 12:21 Uhr - Ignorieren | BM senden - Kommentar: Melden | Zitieren
Beitrag: #1

Postings: 316 - Neuling Ranking
Advanced Viral Res Corp.
News von gestern: Bild

Press Release Source: Advanced Viral Research Corp.

First Patient Enrolled in Phase II Cancer Trial
Wednesday October 3, 6:00 am ET

YONKERS, N.Y.--(BUSINESS WIRE)--A new Phase II open label study at McGill University will explore the effect of an investigational drug on patients with recurrent or advanced cancer. Researchers indicate the treatment may help patients who suffer from severe appetite loss, fatigue and weight loss when undergoing aggressive cancer therapy.

Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - News), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, today announced the enrollment of the first patient into the Phase II clinical trial.

The trial is being conducted at McGill University Health Centre (MUHC) in Montreal, Quebec. Dr. Martin Chasen, a medical oncologist / palliative care physician and Clinical Director of the McGill Cancer Nutrition and Rehabilitation Program at McGill University, is the Principal Investigator.

The Phase II open label study will examine the effect of a 4.0 mL subcutaneous dose of AVR118 on weight, appetite, performance status, and other measures of quality of life in patients with recurrent or advanced malignancies. AVR118 will be administered daily for a trial period of 28 days. Patients who appear to benefit from the trial period dosing will be eligible to continue on AVR118, generating longer term efficacy data.

According to Dr. Chasen, "AVR118 may offer a new treatment paradigm in palliative care. Early identification and treatment of patients will hopefully enable us to reduce the severely debilitating effects of cachexia and chemotherapy."

Enrollment initially will include 14 patients between the ages of 18 and 85 who have recurrent or advanced malignancies and are suffering from symptoms of cachexia, including muscle wasting, severe fatigue and loss of appetite. Pending review of preliminary data, there is a provision to increase enrollment to 30 patients.

"We are excited to have our first patient enrolled at McGill and hope to improve the quality of life for all patients in this trial. Our company remains committed to contributing to cancer symptom control and advancing palliative care research," said Stephen M. Elliston, President and Chief Executive Officer of ADVR.

Advanced Viral Research Corp. is a New York biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the control of symptoms associated with cancer and other serious diseases. Its initial compound AVR118 represents a new class of cytoprotective agent that targets, among other things, cachexia related disorders. Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy. AVR118 has also been shown to have topical wound healing properties in animal models.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

For further information regarding Advanced Viral Research Corp., please visit the website at http://www.adviral.com.


The Signature Agency
Gayle Challinor, 800-870-8700 or 919-878-8989
Advanced Viral Research Corp.
Stephen M. Elliston, 914-376-7383
Fax: 919-878-3939

Source: Advanced Viral Research Corp.
Chefkoch am 04.10.2007 - 15:54 Uhr - Ignorieren | BM senden - Kommentar: Melden | Zitieren
Beitrag: #2

Postings: 316 - Neuling Ranking
Advanced Viral Res Corp.
RT Chart:
Chefkoch am 17.10.2007 - 11:02 Uhr - Ignorieren | BM senden - Kommentar: Melden | Zitieren
Beitrag: #3

Postings: 316 - Neuling Ranking
Advanced Viral Res Corp.
Hält sich sehr gut auf diesem Niveau. Ist nur eine Frage der Zeit wann ADVR ausbricht.

Toptrader am 18.10.2007 - 14:54 Uhr - Ignorieren | BM senden - Kommentar: Melden | Zitieren
Beitrag: #4

Postings: 471 - Neuling Ranking
Advanced Viral Res Corp.
Hier wartet man sich auch einen Wolf. Bild
Chefkoch am 24.10.2007 - 11:02 Uhr - Ignorieren | BM senden - Kommentar: Melden | Zitieren
Beitrag: #5

Postings: 316 - Neuling Ranking
Advanced Viral Res Corp.
Abwarten ist hier angesagt.